Pancreatic Cancer Research

ResearcherSt. Marianna University School of MedicineActive in the last 2 years

Tomoko Norose

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-1846-1838; OpenAlex author ID A5073717640. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 10

  1. Diagnostic performance of droplet digital PCR for KRAS mutation analysis in pancreatic cancer cytology specimens. Co-author DOI 10.1007/s00535-026-02447-9↗
  2. Intraoperative decision-making for pancreatic ductal adenocarcinoma with occult para-aortic lymph node metastasis: Proposal of a pathology-based weighted risk … Co-author DOI 10.1016/j.suronc.2026.102559↗
  3. Impact of tumor necrosis on comprehensive genomic profiling success in pancreatic cancer: a retrospective study. Co-author DOI 10.1093/jjco/hyaf156↗
  4. A Case of Pancreatic Ductal Adenocarcinoma in PRSS1-Associated Hereditary Pancreatitis in the Absence of High-Grade PanIN: Suggestive of Chromothripsis-Like Tu… Co-author DOI 10.1111/pin.70055↗
  5. Corrigendum to Clinical significance of immunocytochemical staining for peritoneal lavage cytology in pancreatic cancer: [Surgery. 2022;172(6):1776-81, DOI: 10… Co-author DOI 10.1016/j.surg.2023.05.001↗
  6. Clinical significance of immunocytochemical staining for peritoneal lavage cytology in pancreatic cancer. Co-author DOI 10.1016/j.surg.2022.09.025↗
  7. A deep learning model to detect pancreatic ductal adenocarcinoma on endoscopic ultrasound-guided fine-needle biopsy. Co-author DOI 10.1038/s41598-021-87748-0↗
  8. High levels of human epididymis protein 4 mRNA and protein expression are associated with chemoresistance and a poor prognosis in pancreatic cancer. Co-author DOI 10.3892/ijo.2020.5147↗
  9. High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0226707↗
  10. High expression levels of polymeric immunoglobulin receptor are correlated with chemoresistance and poor prognosis in pancreatic cancer. Co-author DOI 10.3892/or.2020.7610↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teiichi Sugiura · 3 shared papers, 2022–2026 · strength 0.59
  2. Ryo Ashida · 3 shared papers, 2022–2026 · strength 0.59
  3. Katsuhiko Uesaka · 3 shared papers, 2022–2026 · strength 0.59
  4. Katsuhisa Ohgi · 3 shared papers, 2022–2026 · strength 0.59
  5. Kazunari Nakahara · 2 shared papers, 2025–2026 · strength 0.48
  6. Yu Sunakawa · 2 shared papers, 2025–2026 · strength 0.48
  7. Junki Koike · 2 shared papers, 2025–2026 · strength 0.48
  8. Mihoko Yamada · 2 shared papers, 2022–2023 · strength 0.33
  9. Hidemasa Kubo · 2 shared papers, 2022–2023 · strength 0.33
  10. Yoshiyasu Kato · 1 shared paper, 2026 · strength 0.26
  11. Jun Shibamoto · 1 shared paper, 2026 · strength 0.26
  12. Erica Yada · 3 shared papers, 2020–2021 · strength 0.25
  13. Satoshi Wada · 3 shared papers, 2020–2021 · strength 0.25
  14. Tetsuro Sasada · 3 shared papers, 2020–2021 · strength 0.25
  15. Yutaro Kubota · 3 shared papers, 2020–2021 · strength 0.25
  16. Ryotaro Ohkuma · 3 shared papers, 2020–2021 · strength 0.25
  17. Shinjiro Kobayashi · 1 shared paper, 2025 · strength 0.25
  18. Hiroki Sakamoto · 1 shared paper, 2026 · strength 0.24
  19. Hirotoshi Ishiwatari · 1 shared paper, 2026 · strength 0.24
  20. Takuya Doi · 1 shared paper, 2026 · strength 0.24
  21. Hiroyuki Ono · 1 shared paper, 2026 · strength 0.24
  22. Kumiko Umemoto · 1 shared paper, 2026 · strength 0.23
  23. Hiroyuki Takeda · 1 shared paper, 2026 · strength 0.23
  24. Yosuke Igarashi · 1 shared paper, 2026 · strength 0.23
  25. Aoi Sukeda · 1 shared paper, 2021 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.